Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4402902 | 0.96 | KDM4E (0.43) | KDM4EALDH1A1GAACES2POLB | |
| SCHEMBL20128726 | 0.96 | KDM4E (0.43) | KDM4EALDH1A1GAACES2POLB | |
| SCHEMBL20133152 | 0.96 | KDM4E (0.43) | KDM4EALDH1A1GAACES2POLB | |
| SCHEMBL27408407 | 0.96 | KDM4E (0.43) | KDM4EALDH1A1GAACES2POLB | |
| SCHEMBL13029060 | 0.89 | CES2 (0.44) | KDM4EALDH1A1GAACES2POLB | |
| SCHEMBL20993534 | 0.87 | KDM4E (0.38) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL20234227 | 0.86 | KDM4E (0.37) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL20805331 | 0.85 | CES2 (0.46) | KDM4EALDH1A1GAACES2POLB | |
| SCHEMBL12980779 | 0.84 | KDM4E (0.38) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL10046329 | 0.84 | KDM4E (0.38) | KDM4EALDH1A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-20210347709-A1 | RADIOFLUORINATED GPC3-BINDING PEPTIDES FOR PET IMAGING OF HEPATOCELLULAR CARCINOMA | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-11-11 | — | — | US | disclosed |
| US-9487556-B2 | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo | Arrowhead Pharmaceuticals, Inc. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160271156-A1 | ANTI-CANCER COMPOUNDS AND METHODS FOR TREATING CANCER | UNIV YALE (US) | 2016-09-22 | — | — | US | disclosed |
| US-9346846-B1 | Anti-cancer compounds and methods for treating cancer | YALE UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160082112-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-9005575-B2 | Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | STC.UNM (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2015-02-12 | — | — | US | disclosed |
| US-20120107237-A1 | ARG-GLY-ASP-CONJUGATED ALPHA-MELANOCYTE STIMULATING HORMONE HYBRID PEPTIDE FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME | STC.UNM (US) | 2012-05-03 | — | — | US | disclosed |
| US-20100285144-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100247668-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | KDM4E 4122/4885ALDH1A1 2370/4885GAA 1370/4885 |
| US-20160082112-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | CD47, FCGR1A, FCGR2A | KDM4E 2155/4885ALDH1A1 3701/4885GAA 1108/4885 |
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | PAM, PLAUR, M6PR | KDM4E 1014/4885ALDH1A1 4683/4885GAA 453/4885 |
| US-20160271156-A1 | ANTI-CANCER COMPOUNDS AND METHODS FOR TREATING CANCER | POLM, FOLR1, TYMP | KDM4E 4093/4885ALDH1A1 3781/4885GAA 679/4885 |
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | KDM4E 4481/4885ALDH1A1 1992/4885GAA 114/4885 |
| US-20210347709-A1 | RADIOFLUORINATED GPC3-BINDING PEPTIDES FOR PET IMAGING OF HEPATOCELLULAR CARCINOMA | LGALS3BP, HDGF, LGALS3 | KDM4E 3826/4885ALDH1A1 4235/4885GAA 3060/4885 |
| US-20120107237-A1 | ARG-GLY-ASP-CONJUGATED ALPHA-MELANOCYTE STIMULATING HORMONE HYBRID PEPTIDE FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME | MC1R, MC3R, MC4R | KDM4E 3634/4885ALDH1A1 4408/4885GAA 3528/4885 |
| US-20100247668-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | KDM4E 4481/4885ALDH1A1 1992/4885GAA 114/4885 |
| US-20100285144-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | EPOR, TTPA, PDS5A | KDM4E 4450/4885ALDH1A1 859/4885GAA 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.